Cannabis, Nicotine, and Other Substance Disorders

This topic covers substance use disorders arising from cannabis, nicotine (tobacco), and additional substance classes such as sedatives, hypnotics, hallucinogens, and inhalants. Each is diagnosed by the standard substance use disorder criteria, but the classes differ in their pharmacology, withdrawal profiles, and public-health significance — nicotine being one of the most widely used dependence-producing substances and cannabis the most commonly used illicit substance in many regions.

Definition

These disorders are problematic patterns of use of cannabis, nicotine, or other psychoactive substance classes leading to clinically significant impairment or distress, each diagnosed by the standard substance use disorder criteria applied to the relevant substance.

Scope

The entry orients readers to how these varied substance classes are classified within addiction nosology and to their distinguishing features, with emphasis on cannabis and nicotine. It is a reference and educational overview; it describes the disorders and their evidence base and does not provide diagnostic thresholds for individuals or any treatment or cessation instructions.

Core questions

• How are cannabis, nicotine, and other less-grouped substance disorders classified?
• How do their pharmacology and withdrawal profiles differ from one another?
• What is the public-health significance of cannabis and nicotine use disorders?

Key concepts

• Cannabis use disorder
• Tetrahydrocannabinol and cannabinoid receptors
• Nicotine dependence
• Tobacco-related harm
• Sedative, hypnotic, and anxiolytic disorders
• Hallucinogen and inhalant use
• Withdrawal profiles by class

Key theories

Shared diagnostic template across diverse substances

Despite differing mechanisms, cannabis, nicotine, and other substance disorders are defined by the same eleven-criterion DSM-5 template, reflecting the view that a common syndrome of impaired control and continued use despite harm spans substance classes.

Mechanisms

These substance classes act through distinct pathways: cannabis via cannabinoid receptors (chiefly through delta-9-tetrahydrocannabinol), nicotine via nicotinic acetylcholine receptors, and sedative-hypnotics largely through GABAergic systems, among others. Each can produce reinforcement, and several have recognized withdrawal syndromes (for example cannabis and nicotine withdrawal were formalized in DSM-5). Despite these mechanistic differences, the disorders are diagnosed by the same criteria, and their classification rests on the common pattern of impaired control, social impairment, risky use, and pharmacological features.

Clinical relevance

Cannabis and nicotine use disorders are highly prevalent and carry substantial population health impact — tobacco being a leading preventable cause of death — so their classification matters for case identification and epidemiology. This entry is educational reference material and does not provide individual diagnostic thresholds or any treatment, cessation, or dosing guidance.

Epidemiology

Tobacco use is responsible for a large share of preventable global mortality, and cannabis is among the most widely used psychoactive substances, with a proportion of users developing a use disorder; prospective data also link cannabis use to elevated risk of certain psychiatric outcomes.

Evidence & guidelines

Cannabis use disorder, tobacco use disorder, and the other substance-class disorders are defined within DSM-5 (American Psychiatric Association, 2013) and ICD-11. Volkow and colleagues (2014) review adverse effects of cannabis, Blanco and colleagues (2016) report prospective associations with psychiatric disorders, and Jha and Peto (2014) summarize the global health effects of tobacco.

History

Earlier classifications often treated tobacco dependence and cannabis problems unevenly. DSM-5 (2013) formalized cannabis use disorder and tobacco use disorder under the unified substance use disorder framework and recognized cannabis and tobacco withdrawal syndromes, aligning these classes with the broader nosology while ICD-11 organized them within its disorders-due-to-substance-use chapter.

Debates

Cannabis use and psychiatric risk

Prospective studies have associated cannabis use with increased risk of some psychiatric disorders, but disentangling causation from confounding and reverse causation remains contested and bears on how the public-health significance of cannabis use disorder is framed.

Key figures

• Nora Volkow
• Carlos Blanco
• Prabhat Jha
• Richard Peto

Seminal works

• volkow-2014
• jha-2014
• apa-dsm5-2013

Frequently asked questions

Are cannabis and nicotine use disorders diagnosed the same way as other substance use disorders?

Yes; DSM-5 applies the same eleven-criterion template to cannabis use disorder and tobacco use disorder as to other substance classes, with severity graded by the number of criteria met.

What other substances fall under this topic?

Besides cannabis and nicotine, it covers sedative, hypnotic, and anxiolytic disorders, hallucinogen-related disorders, and inhalant use disorder — classes that are diagnosed by the same criteria but differ in mechanism and withdrawal profile.